Emergent Biosolutions Inc. Stock
A loss of -2.020% shows a downward development for Emergent Biosolutions Inc..
Emergent Biosolutions Inc. is currently one of the favorites of our community with 9 Buy predictions and no Sell predictions.
With a target price of 14 € there is a positive potential of 41.79% for Emergent Biosolutions Inc. compared to the current price of 9.87 €.
Our community identified positive and negative aspects for Emergent Biosolutions Inc. stock for the coming years. 1 users see the criterium "Company culture" as a plus for the Emergent Biosolutions Inc. stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Emergent Biosolutions Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
B****
Cons
?
C******** o* t** e**********
?
M***** P*******
?
S********** s********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Emergent Biosolutions Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Emergent Biosolutions Inc. | -2.020% | -0.664% | 3.937% | 20.857% | 26.720% | -16.421% | -85.690% |
| Ironwood Pharmaceuticals | 3.290% | -3.797% | 84.242% | -12.644% | -27.619% | -72.543% | -69.293% |
| Novocure Ltd | 3.110% | 11.759% | 16.191% | -59.936% | -61.161% | -84.188% | -91.887% |
| Iovance Biotherapeutics Inc. | -0.120% | 2.465% | -5.304% | -76.280% | -71.952% | -70.459% | -95.240% |
Comments
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) was upgraded by analysts at Wall Street Zen from a "buy" rating to a "strong-buy" rating.
Show more
Ratings data for EBS provided by MarketBeat
Emergent Biosolutions (NYSE:EBS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $15.00 price target on the stock.
Show more
Ratings data for EBS provided by MarketBeat